Page last updated: 2024-11-12

nemonoxacin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

nemonoxacin: has antibacterial activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11993740
CHEMBL ID1213456
CHEBI ID136053
SCHEMBL ID1006373
MeSH IDM0539102

Synonyms (26)

Synonym
CHEMBL1213456
CHEBI:136053
nemonoxacin
tg-873870
p94l0pvo94 ,
tg873870
tg 873870
nemonoxacin [inn]
378746-64-6
unii-p94l0pvo94
SCHEMBL1006373
3-quinolinecarboxylic acid, 7-((3s,5s)-3-amino-5-methyl-1-piperidinyl)-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-
nemonoxacin [who-dd]
7-[(3s,5s)-3-amino-5-methylpiperidin-1-yl]-1-cyclopropyl-8-methoxy-4- oxo-1,4-dihydroquinoline-3-carboxylic acid
7-[(3s,5s)-3-amino-5-methylpiperidin-1-yl]-1-cyclopropyl-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
7-((3s,5s)-3-amino-5-methylpiperidin-1-yl)-1-cyclopropyl-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
DB06600
Q15425793
gtpl10836
7-[(3s,5s)-3-amino-5-methylpiperidin-1-yl]-1-cyclopropyl-8-methoxy-4-oxoquinoline-3-carboxylic acid
MS-25985
DTXSID10958907
TQP0855
HY-14956
CS-0003656
STARBLD0028467

Research Excerpts

Overview

Nemonoxacin (TG-873870) is a novel nonfluorinated quinolone with broad-spectrum activities against Gram-positive and Gram-negative aerobic, anaerobic, and atypical pathogens. It has strong antibacterial efficacy, but data of its effect on acute exacerbations of chronic obstructive pulmonary disease (AECOPD) is rare.

ExcerptReferenceRelevance
"Nemonoxacin (TG-873870) is a novel nonfluorinated quinolone with potent broad-spectrum activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus, penicillin- and quinolone-resistant Streptococcus pneumoniae, and vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. "( Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
Ajayi, F; Aronstein, WS; Chang, LW; Chung, DT; Hsu, CH; Kuzmak, B; Lin, L; Lyon, RA; Tsai, CY, 2010
)
2.03
"Nemonoxacin (TG-873870) is a novel nonfluorinated quinolone with broad-spectrum activities against Gram-positive and Gram-negative aerobic, anaerobic, and atypical pathogens, as well as against methicillin-resistant Staphylococcus aureus, vancomycin-resistant S. "( Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
Chang, LW; Chang, YT; Chen, SJ; Chiu, KM; Chung, DT; Hsu, CH; Hsu, MC; King, CH; Tan, HC; Tsai, CY, 2010
)
2.04
"Nemonoxacin is a novel non-fluorinated quinolone with strong antibacterial efficacy, but data of its effect on acute exacerbations of chronic obstructive pulmonary disease (AECOPD) is rare. "( Nemonoxacin achieved a better symptomatic improvement and a prolonged interval to next exacerbation than moxifloxacin for outpatients with acute exacerbations of chronic obstructive pulmonary disease.
Chen, Y; Li, Z; Meng, W; Xiong, R; Zeng, H; Zhao, Z, 2023
)
3.8
"Nemonoxacin is a nonfluorinated quinolone with good bactericidal effects against quinolone-resistant Gram-positive microorganisms. "( Selected Mutations by Nemonoxacin and Fluoroquinolone Exposure Among Relevant Gram-Positive Bacterial Strains in Taiwan.
Chang, LW; Cheng, A; Hsu, MC; Sheng, WH; Tai, HM; Yang, JJ, 2020
)
2.32
"Nemonoxacin is a novel non-fluorinated quinolone. "( Nemonoxacin Has Immunoprotective Effects on Reducing Mortality in Lipopolysaccharide-Induced Mouse Sepsis Model.
Chen, N; Feng, M; Guo, B; Huang, J; Li, X; Lin, D; Zhao, X; Zou, J, 2020
)
3.44
"Nemonoxacin is a novel nonfluorinated quinolone with excellent in vitro activity against most pathogens in community-acquired pneumonia (CAP), especially Gram-positive isolates. "( Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial.
Cao, Z; Chang, L; Cheng, SL; Lv, Y; Ma, Z; Mo, B; Sun, S; Tong, Z; Wu, J; Wu, R; Yang, Y; Yuan, J; Zhang, Y; Zhu, D, 2019
)
2.25
"Nemonoxacin is a novel C-8-methoxy nonfluorinated quinolone that has been approved for the treatment of community-acquired pneumonia (CAP) in adults. "( Population Pharmacokinetics Study of Nemonoxacin Among Chinese Patients With Moderate Hepatic Impairment.
Chen, Y; Guo, B; Kang, Y; Li, Y; Wang, K; Wu, J; Xu, F; Yu, J; Zhang, J; Zhang, Y, 2019
)
2.23
"Nemonoxacin is a novel C-8-methoxy nonfluorinated quinolone with remarkably enhanced in vitro activity against a wide variety of clinically relevant pathogens, especially gram-positive bacteria, including multidrug-resistant Streptococcus pneumoniae and methicillin-resistant Staphylococcus aureus. "( Review of nemonoxacin with special focus on clinical development.
Huang, H; Qin, X, 2014
)
2.25
"Nemonoxacin (TG-873870) is a novel nonfluorinated quinolone with potent broad-spectrum activity against Gram-positive, Gram-negative, and atypical pathogens, including vancomycin-nonsusceptible methicillin-resistant Staphylococcus aureus (MRSA), quinolone-resistant MRSA, quinolone-resistant Streptococcus pneumoniae, penicillin-resistant S. "( Safety, tolerability, and pharmacokinetics of intravenous nemonoxacin in healthy chinese volunteers.
Cao, GY; Chen, YC; Guo, BN; Shi, YG; Wu, JF; Wu, XJ; Yu, JC; Zhang, J; Zhang, YY, 2014
)
2.09
"Nemonoxacin (TG-873870) is a novel C-8-methoxy nonfluorinated quinolone with higher activity than ciprofloxacin, levofloxacin and moxifloxacin against Gram-positive pathogens including methicillin-susceptible or methicillin-resistant Staphylococcus aureus and Streptococcus pneumoniae with various resistant phenotypes. "( A liquid chromatography-tandem mass spectrometry assay for the determination of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, in human plasma and urine and its application to a single-dose pharmacokinetic study in healthy Chinese volunteers.
Guo, B; Shi, Y; Tsai, CY; Wu, X; Yu, J; Zhang, J, 2012
)
2.05

Effects

ExcerptReferenceRelevance
"Nemonoxacin has a sound PK profile in healthy volunteers."( Review of nemonoxacin with special focus on clinical development.
Huang, H; Qin, X, 2014
)
1.53
"Oral nemonoxacin has been approved in Taiwan for the treatment of CAP in adults."( Nemonoxacin: first global approval.
Poole, RM, 2014
)
2.3

Actions

ExcerptReferenceRelevance
"Nemonoxacin showed lower MICs against clinical C."( The potential role of nemonoxacin for treatment of common infections.
Chen, YH; Hsueh, PR; Huang, CH; Lai, CC, 2015
)
1.45

Toxicity

Nemonoxacin was generally safe and well tolerated, with no significant changes in the clinical laboratory tests or electrocardiograms. The incidence of adverse events (AEs) was comparable between nemonxacin (33%) and levofloxacins (33%).

ExcerptReferenceRelevance
" No severe or serious adverse events were observed."( Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
Ajayi, F; Aronstein, WS; Chang, LW; Chung, DT; Hsu, CH; Kuzmak, B; Lin, L; Lyon, RA; Tsai, CY, 2010
)
0.59
" Nemonoxacin was generally safe and well tolerated, with no significant changes in the clinical laboratory tests or electrocardiograms."( Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
Chang, LW; Chang, YT; Chen, SJ; Chiu, KM; Chung, DT; Hsu, CH; Hsu, MC; King, CH; Tan, HC; Tsai, CY, 2010
)
1.51
" All three treatments were well tolerated, and no drug-related serious adverse events were observed."( Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia.
Bester, AJ; Chang, LW; Chang, YT; Chung, DT; Ho, ML; Hsu, MC; Kasumba, J; King, CH; Mitha, IH; Perng, RP; van Rensburg, DJ; Wu, RG, 2010
)
0.67
"No severe or serious adverse events (AEs) occurred in this study, and no clinically significant abnormalities were noted in the vital signs or on physical examination."( Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses.
Cao, G; Guo, B; Shi, Y; Wu, X; Yu, J; Zhang, J; Zhang, Y, 2012
)
0.65
" Drug-related adverse events (AEs) were mild, transient, and confined to local irritation at the injection site."( Safety, tolerability, and pharmacokinetics of intravenous nemonoxacin in healthy chinese volunteers.
Cao, GY; Chen, YC; Guo, BN; Shi, YG; Wu, JF; Wu, XJ; Yu, JC; Zhang, J; Zhang, YY, 2014
)
0.65
" Most drug-related adverse events were mild and transient, mainly gastrointestinal symptoms such as nausea and vomiting, transient neutropenia, and elevated liver enzymes."( A randomized, double-blind, multicenter Phase II study comparing the efficacy and safety of oral nemonoxacin with oral levofloxacin in the treatment of community-acquired pneumonia.
Cao, Z; Chang, L; Chen, P; Cui, S; Hu, C; Kuang, J; Li, J; Liang, Y; Liu, H; Liu, S; Liu, Y; Lv, X; Lv, Y; Ren, Z; Sun, S; Wang, C; Wang, D; Wang, X; Wu, J; Xiao, Z; Xiu, Q; Yang, H; Zhang, Y; Zhao, L; Zhu, D, 2017
)
0.67
" Clinical, microbiological response and adverse events were assessed."( Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial.
Cao, Z; Chang, L; Cheng, SL; Lv, Y; Ma, Z; Mo, B; Sun, S; Tong, Z; Wu, J; Wu, R; Yang, Y; Yuan, J; Zhang, Y; Zhu, D, 2019
)
0.81
" The incidence of adverse events (AEs) was comparable between nemonoxacin (33."( Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial.
Cao, Z; Chang, L; Cheng, SL; Lv, Y; Ma, Z; Mo, B; Sun, S; Tong, Z; Wu, J; Wu, R; Yang, Y; Yuan, J; Zhang, Y; Zhu, D, 2019
)
1.05
"Nemonoxacin 500 mg once daily for 7-10 days is as effective and safe as levofloxacin for treating adult CAP patients in terms of clinical cure rates, microbiological success rates, and safety profile."( Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial.
Cao, Z; Chang, L; Cheng, SL; Lv, Y; Ma, Z; Mo, B; Sun, S; Tong, Z; Wu, J; Wu, R; Yang, Y; Yuan, J; Zhang, Y; Zhu, D, 2019
)
2.25
" The incidence of adverse events (AEs) was the highest (54."( Integrated safety summary of phase II and III studies comparing oral nemonoxacin and levofloxacin in community-acquired pneumonia.
Chang, LW; Chang, YT; Cheng, SL; Chuang, YC; Hsu, MC; Perng, WC; Tsao, SM; Wu, RG, 2019
)
0.75

Pharmacokinetics

The method was successfully applied to a pharmacokinetic study enrolling 12 healthy Chinese volunteers. The peak time and elimination half-life of nemonoxacin were 1 to 2 h and 9 to 16 h, respectively. This first-in-human study was aimed at assessing the safety, tolerability, and pharmacokinetics properties of intravenous nemon Oxacin.

ExcerptReferenceRelevance
" The peak time and elimination half-life of nemonoxacin were 1 to 2 h and 9 to 16 h, respectively."( Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
Ajayi, F; Aronstein, WS; Chang, LW; Chung, DT; Hsu, CH; Kuzmak, B; Lin, L; Lyon, RA; Tsai, CY, 2010
)
0.85
" The method was successfully applied to a pharmacokinetic study enrolling 12 healthy Chinese volunteers administered nemonoxacin malate capsules."( A liquid chromatography-tandem mass spectrometry assay for the determination of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, in human plasma and urine and its application to a single-dose pharmacokinetic study in healthy Chinese volunteers.
Guo, B; Shi, Y; Tsai, CY; Wu, X; Yu, J; Zhang, J, 2012
)
0.82
" The elimination half-life was 10-12 hours."( Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses.
Cao, G; Guo, B; Shi, Y; Wu, X; Yu, J; Zhang, J; Zhang, Y, 2012
)
0.65
" When the MIC is high, the time (T) dependency is important and the valid PK/PD index should be the cumulative percentage of a 24-h period in which the drug concentration exceeds the MIC under steady-state pharmacokinetic conditions (f%T>MIC), which means that to split the maximum daily dose into several separate doses will benefit the eradication of the bacteria."( Pharmacokinetics and pharmacodynamics of nemonoxacin against Streptococcus pneumoniae in an in vitro infection model.
Cao, YR; Chen, YC; Guo, QL; Hu, JL; Huang, J; Liang, W; Liu, XF; Wu, XJ; Zhang, J; Zhang, SJ; Zhang, YY; Zhao, M; Zhu, DM, 2013
)
0.66
" This first-in-human study was aimed at assessing the safety, tolerability, and pharmacokinetic properties of intravenous nemonoxacin in healthy Chinese volunteers."( Safety, tolerability, and pharmacokinetics of intravenous nemonoxacin in healthy chinese volunteers.
Cao, GY; Chen, YC; Guo, BN; Shi, YG; Wu, JF; Wu, XJ; Yu, JC; Zhang, J; Zhang, YY, 2014
)
0.85
" This review focuses on recent advances concerning quinolones and fluoroquinolones, we will be summarising chemical structure, mode of action, pharmacokinetic properties and toxicity."( Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin.
Domokos, J; Kocsis, B; Szabo, D, 2016
)
0.64
" The goals of this study were to evaluate the pharmacokinetic (PK) and population PK parameters of nemonoxacin and to provide the appropriate dose adjustment recommendations for patients with hepatic impairment."( Population Pharmacokinetics Study of Nemonoxacin Among Chinese Patients With Moderate Hepatic Impairment.
Chen, Y; Guo, B; Kang, Y; Li, Y; Wang, K; Wu, J; Xu, F; Yu, J; Zhang, J; Zhang, Y, 2019
)
1
"To optimize the dosing regimen in patients with severe renal impairment based on population pharmacokinetic (PPK)/pharmacodynamic analysis."( Nemonoxacin dosage adjustment in patients with severe renal impairment based on population pharmacokinetic and pharmacodynamic analysis.
Chen, Y; Fan, Y; Guo, B; Hu, J; Kang, Y; Li, X; Li, Y; Liu, X; Lu, J; Wang, K; Wang, Y; Wu, H; Wu, J; Xu, X; Xue, J; Yu, J; Zeng, X; Zhang, J; Zhang, Y; Zhao, M, 2021
)
2.06

Bioavailability

ExcerptReferenceRelevance
" The validated methods were successfully applied to an absolute bioavailability clinical study of nemonoxacin malate capsule."( Determination of a novel nonfluorinated quinolone, nemonoxacin, in human feces and its glucuronide conjugate in human urine and feces by high-performance liquid chromatography-triple quadrupole mass spectrometry.
Cao, G; Guo, B; He, G; Shi, Y; Tsai, CY; Wu, X; Yu, J; Zhang, J, 2015
)
0.89

Dosage Studied

Nemonoxacin 0.5-750 mg exhibited a linear dose-response relationship between the AUC0-72 h and A UC0-∞. PPK/pharmacodynamic modelling and simulation of 4 dosage regimens found that nemonxacin was safe to use once daily.

ExcerptRelevanceReference
" The maximum plasma concentration and the area under the plasma concentration-time curve were dose proportional over the dosing range."( Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
Chang, LW; Chang, YT; Chen, SJ; Chiu, KM; Chung, DT; Hsu, CH; Hsu, MC; King, CH; Tan, HC; Tsai, CY, 2010
)
0.6
" The PK and safety profiles of nemonoxacin in Chinese subjects support evaluation of once-daily dosing in the future development of this agent."( Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses.
Cao, G; Guo, B; Shi, Y; Wu, X; Yu, J; Zhang, J; Zhang, Y, 2012
)
0.93
" Volunteers treated with 250 to 750 mg nemonoxacin exhibited a linear dose-response relationship between the AUC0-72 h and AUC0-∞."( Safety, tolerability, and pharmacokinetics of intravenous nemonoxacin in healthy chinese volunteers.
Cao, GY; Chen, YC; Guo, BN; Shi, YG; Wu, JF; Wu, XJ; Yu, JC; Zhang, J; Zhang, YY, 2014
)
0.92
" A Monte Carlo simulation indicated that the cumulative fraction of response of any dosing regimen was nearly 100% against Streptococcus pneumoniae."( Pharmacokinetics and pharmacodynamics of multiple-dose intravenous nemonoxacin in healthy Chinese volunteers.
Cao, GY; Chang, LW; Chang, YT; Chen, YC; Guo, BN; Shi, YG; Tsai, CY; Wu, JF; Wu, XJ; Ye, XY; Yu, JC; Zhang, J; Zhang, YY; Zhu, DM, 2015
)
0.65
"To optimize the dosing regimen in patients with severe renal impairment based on population pharmacokinetic (PPK)/pharmacodynamic analysis."( Nemonoxacin dosage adjustment in patients with severe renal impairment based on population pharmacokinetic and pharmacodynamic analysis.
Chen, Y; Fan, Y; Guo, B; Hu, J; Kang, Y; Li, X; Li, Y; Liu, X; Lu, J; Wang, K; Wang, Y; Wu, H; Wu, J; Xu, X; Xue, J; Yu, J; Zeng, X; Zhang, J; Zhang, Y; Zhao, M, 2021
)
2.06
"An extended dosing interval (0."( Nemonoxacin dosage adjustment in patients with severe renal impairment based on population pharmacokinetic and pharmacodynamic analysis.
Chen, Y; Fan, Y; Guo, B; Hu, J; Kang, Y; Li, X; Li, Y; Liu, X; Lu, J; Wang, K; Wang, Y; Wu, H; Wu, J; Xu, X; Xue, J; Yu, J; Zeng, X; Zhang, J; Zhang, Y; Zhao, M, 2021
)
2.06
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
quinolinesA class of aromatic heterocyclic compounds each of which contains a benzene ring ortho fused to carbons 2 and 3 of a pyridine ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (438)

Assay IDTitleYearJournalArticle
AID495544Toxicity in human assessed as occurrence of somnolence at 1000 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID570925Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 64 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495607Renal clearance in human at 500 mg/kg, po measured on day 102010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571353Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570928Antibacterial activity against methicillin-susceptible Staphylococcus epidermidis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571363Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of >=512 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570683Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.015 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495476Clearance in healthy human assessed as recovery of unchanged drug in urine at 125 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570685Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571359Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 32 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571361Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 128 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570696Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.015 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495433Cmax in healthy human at 50 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495578Terminal half life in human at 75 mg/kg, po measured on day 102010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495537Toxicity in human assessed as occurrence of diarrhea at 1000 mgkg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495787Cmax in human at 500 mg/kg, po measured on day 162010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID570668Antibacterial activity against Staphylococcus aureus by CLSI M7-A7 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495482Antimicrobial activity against penicillin-sensitive Streptococcus pneumoniae2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495388Toxicity in healthy human assessed as occurrence of headache at 1000 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570701Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570708Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 64 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495387Toxicity in healthy human assessed as occurrence of headache at 500 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495424Toxicity in healthy human assessed as occurrence of ear pain at 1500 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570694Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 32 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495463Clearance in healthy human at 250 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570664Antibacterial activity against methicillin-susceptible Staphylococcus aureus by CLSI M7-A7 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495472Renal clearance in healthy human at 1000 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570665Antibacterial activity against methicillin-resistant Staphylococcus aureus by CLSI M7-A7 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495494Ratio of fAUC to MIC90 for methicillin-resistant Staphylococcus aureus2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570675Antibacterial activity against Stenotrophomonas maltophilia by CLSI M7-A7 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571381Antibacterial activity against Klebsiella oxytoca assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571382Antibacterial activity against Klebsiella oxytoca assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570687Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495533Toxicity in human assessed as occurrence of pruritus at 750 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495577Terminal half life in human at 750 mg/kg, po measured on day 102010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID570917Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570901Antibacterial activity against non-levofloxacin susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 8 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570702Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495611Renal clearance in human at 1000 mg/kg, po measured on day 12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571366Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495465Clearance in healthy human at 1000 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571141Antibacterial activity against Enterococcus faecalis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495442Tmax in healthy human at 250 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570688Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571358Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 16 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495455Terminal volume of distribution in healthy human at 125 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495584Clearance in human assessed as compound recovered in urine at 250 mg/kg, po measured on day 1 up to 24 hrs post dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID570909Antibacterial activity against community-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495471Renal clearance in healthy human at 500 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495569AUC (0 to 24 hrs) in human at 75 mg/kg, po measured on day 12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495610Renal clearance in human at 750mg/kg, po measured on day 102010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495528Toxicity in human assessed as occurrence of abdominal pain at 750 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495621AUC (0 to 24 hrs) in human at 500 mg/kg, po measured on day 12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571848Antibacterial activity against Proteus mirabilis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of >=512 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495591Clearance in human assessed as compound recovered in urine at 1000 mg/kg, po measured on day 1 up to 24 hrs post dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571869Antibacterial activity against Stenotrophomonas maltophilia assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495419Toxicity in healthy human assessed as occurrence of ear pain at 50 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495623AUC(0 to last) in human at 500 mg/kg, po measured on day 12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495572AUC (0 to last) in human at 250 mg/kg, po measured on day 102010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495499Ratio of fCmax to MIC90 for ciprofloxacin-resistant Streptococcus pneumoniae2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495403Toxicity in healthy human assessed as occurrence of abdominal pain at 1500 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570706Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 16 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571881Antibacterial activity against Acinetobacter baumannii assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 16 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495556Tmax in human at 75 mg/kg, po measured on day 12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID570918Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495604Renal clearance in human at 250 mg/kg, po measured on day 12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID570898Antibacterial activity against non-levofloxacin susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570920Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495429AUC (0 to infinity) in healthy human at 500 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570921Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495583Clearance in human assessed as compound recovered in urine at 75 mg/kg, po measured on day 10 up to 24 hrs post dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495441Tmax in healthy human at 125 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570900Antibacterial activity against non-levofloxacin susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495600Oral clearance in human at 1000 mg/kg measured on day 12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495573AUC (0 to 24 hrs) in human at 750 mg/kg, po measured on day 12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495428AUC (0 to infinity) in healthy human at 250 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571878Antibacterial activity against Acinetobacter baumannii assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495647Toxicity in healthy human assessed as occurrence of erythema at 125 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570705Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 8 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495530Toxicity in human assessed as occurrence of pruritus at 75 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571843Antibacterial activity against Proteus mirabilis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495480Clearance in healthy human assessed as recovery of unchanged drug in urine at 1500 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495439Tmax in healthy human at 25 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495567Tmax in human at 1000 mg/kg, po measured on day 12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571850Antibacterial activity against Pseudomonas aeruginosa assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571847Antibacterial activity against Proteus mirabilis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 32 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570899Antibacterial activity against non-levofloxacin susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495532Toxicity in human assessed as occurrence of pruritus at 500 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495400Toxicity in healthy human assessed as occurrence of abdominal pain at 250 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571345Antibacterial activity against Enterococcus faecium assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 32 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571844Antibacterial activity against Proteus mirabilis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495401Toxicity in healthy human assessed as occurrence of abdominal pain at 500 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495421Toxicity in healthy human assessed as occurrence of ear pain at 250 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570896Antibacterial activity against non-levofloxacin susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495627Plasma protein binding in human2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495602Renal clearance in human at 75 mg/kg, po measured on day 12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495523Toxicity in human assessed as occurrence of rashes at 75 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571867Antibacterial activity against Stenotrophomonas maltophilia assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570697Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.03 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570927Antibacterial activity against methicillin-susceptible Staphylococcus epidermidis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.03 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495431AUC (0 to infinity) in healthy human at 1500 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495538Toxicity in human assessed as occurrence of pollakiuria at 75 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571842Antibacterial activity against Proteus mirabilis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570672Antibacterial activity against Enterococcus faecium by CLSI M7-A7 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495366Toxicity in healthy human assessed as occurrence of contact dermatitis at 25 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495481Antimicrobial activity against Streptococcus pneumoniae2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571841Antibacterial activity against Proteus mirabilis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495405Toxicity in healthy human assessed as occurrence of pustular rashes at 50 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495468Renal clearance in healthy human at 50 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495617AUC (0 to 24 hrs) in human at 750 mg/kg, po measured on day 102010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID570667Antibacterial activity against community-associated methicillin-resistant Staphylococcus aureus by CLSI M7-A7 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571130Antibacterial activity against penicillin-resistant Streptococcus pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.015 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495413Toxicity in healthy human assessed as occurrence of nausea at 125 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495497Ratio of fCmax to MIC90 for penicillin-intermediate Streptococcus pneumoniae2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495727Clearance in healthy human assessed as recovery of unchanged drug in urine at 25 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570690Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495615AUC (0 to 24 hrs) in human at 250 mg/kg, po measured on day 102010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571365Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.03 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570916Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495450Terminal phase elimination half-life in healthy human at 500 mg/kg, po administered single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570671Antibacterial activity against Enterococcus faecalis by CLSI M7-A7 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571380Antibacterial activity against Klebsiella oxytoca assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571342Antibacterial activity against Enterococcus faecium assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495483Antimicrobial activity against penicillin-intermediate Streptococcus pneumoniae2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495469Renal clearance in healthy human at 125 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495380Toxicity in healthy human assessed as occurrence of erythema at 500 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495460Clearance in healthy human at 25 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495399Toxicity in healthy human assessed as occurrence of abdominal pain at 125 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495566Tmax in human at 750 mg/kg, po measured on day 102010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID570923Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 16 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495500Ratio of fCmax to MIC90 for methicillin-sensitive Staphylococcus aureus2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570932Antibacterial activity against methicillin-susceptible Staphylococcus epidermidis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495599Oral clearance in human at 500 mg/kg measured on day 162010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571118Antibacterial activity against Streptococcus pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.015 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495601Oral clearance in human at 1000 mg/kg measured on day 102010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495521Toxicity in human assessed as occurrence of dermatitis at 500 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495575AUC (0 to 24 hrs) in human at 1000 mg/kg, po measured on day 12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495394Toxicity in healthy human assessed as occurrence of oral hypoesthesia at 500 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495432Cmax in healthy human at 25 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495410Toxicity in healthy human assessed as occurrence of pustular rashes at 1500 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495570AUC (0 to last) in human at 75 mg/kg, po measured on day 102010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495435Cmax in healthy human at 250 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495488Ratio of fAUC to MIC90 for Streptococcus pneumoniae2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495559AUC (0 to 24 hrs)in human at 500 mg/kg, po measured on day 102010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571853Antibacterial activity against Pseudomonas aeruginosa assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571836Antibacterial activity against Enterobacter cloacae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 16 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570929Antibacterial activity against methicillin-susceptible Staphylococcus epidermidis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495589Clearance in human assessed as compound recovered in urine at 750 mg/kg, po measured on day 1 up to 24 hrs post dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495562Tmax in human at 500 mg/kg, po measured on day 12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571862Antibacterial activity against Pseudomonas aeruginosa assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of >=512 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495588Clearance in human assessed as compound recovered in urine at 500 mg/kg, po measured on day 16 up to 24 hrs post dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571852Antibacterial activity against Pseudomonas aeruginosa assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495526Toxicity in human assessed as occurrence of abdominal pain at 250 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495375Toxicity in healthy human assessed as occurrence of pruritus at 1500 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495603Renal clearance in human at 75 mg/kg, po measured on day 102010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495364Toxicity in healthy human assessed as occurrence of contact dermatitis at 125 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495495Ratio of fCmax to MIC90 for Streptococcus pneumoniae2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571860Antibacterial activity against Pseudomonas aeruginosa assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 128 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495367Toxicity in healthy human assessed as occurrence of contact dermatitis at 1000 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495557Tmax in human at 250 mg/kg, po measured on day 12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495417Toxicity in healthy human assessed as occurrence of nausea at 1500 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570887Antibacterial activity against Levofloxacin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.015 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495420Toxicity in healthy human assessed as occurrence of ear pain at 125 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570926Antibacterial activity against methicillin-susceptible Staphylococcus epidermidis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.015 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495436Cmax in healthy human at 500 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495427AUC (0 to infinity) in healthy human at 125 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495440Tmax in healthy human at 50 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571348Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of <=0.015 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571338Antibacterial activity against Enterococcus faecium assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570676Antibacterial activity against Acinetobacter baumannii by CLSI M7-A7 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571370Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495386Toxicity in healthy human assessed as occurrence of headache at 250 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571343Antibacterial activity against Enterococcus faecium assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 8 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495371Toxicity in healthy human assessed as occurrence of pruritus at 125 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495408Toxicity in healthy human assessed as occurrence of pustular rashes at 500 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495586Clearance in human assessed as compound recovered in urine at 500 mg/kg, po measured on day 1 up to 24 hrs post dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495498Ratio of fCmax to MIC90 for penicillin-resistant Streptococcus pneumoniae2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495598Oral clearance in human at 500 mg/kg measured on day 102010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495594Oral clearance in human at 75 mg/kg measured on day 102010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495383Toxicity in healthy human assessed as occurrence of headache at 25 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495574AUC (0 to last) in human at 750 mg/kg, po measured on day 102010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495612Renal clearance in human at 1000 mg/kg, po measured on day 102010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495529Toxicity in human assessed as occurrence of abdominal pain at 1000 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495553Cmax in human at 750 mg/kg, po measured on day 102010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495422Toxicity in healthy human assessed as occurrence of ear pain at 500 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495585Clearance in human assessed as compound recovered in urine at 250 mg/kg, po measured on day 10 up to 24 hrs post dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495605Renal clearance in human at 250 mg/kg, po measured on day 102010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495596Oral clearance in human at 250 mg/kg measured on day 102010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID570700Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571105Antibacterial activity against methicillin-susceptible Staphylococcus epidermidis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570905Antibacterial activity against community-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.015 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495437Cmax in healthy human at 1000 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495398Toxicity in healthy human assessed as occurrence of abdominal pain at 50 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495625Oral clearance in human at 750 mg/kg measured on day 12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571347Antibacterial activity against Enterococcus faecium assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 128 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570906Antibacterial activity against community-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571351Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495501Ratio of fCmax to MIC90 for methicillin-resistant Staphylococcus aureus2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495425AUC (0 to infinity) in healthy human at 25 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570689Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495535Toxicity in human assessed as occurrence of diarrhea at 500 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495473Renal clearance in healthy human at 1500 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495389Toxicity in healthy human assessed as occurrence of headache at 1500 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495619AUC (0 to 24 hrs) in human at 1000 mg/kg, po measured on day 102010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495489Ratio of fAUC to MIC90 for Penicillin-sensitive Streptococcus pneumoniae2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495396Toxicity in healthy human assessed as occurrence of oral hypoesthesia at 1500 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495434Cmax in healthy human at 125 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571120Antibacterial activity against Streptococcus pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571872Antibacterial activity against Stenotrophomonas maltophilia assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 32 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495393Toxicity in healthy human assessed as occurrence of oral hypoesthesia at 250 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495395Toxicity in healthy human assessed as occurrence of oral hypoesthesia at 1000 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570684Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.03 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495444Tmax in healthy human at 1000 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571121Antibacterial activity against Streptococcus pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495458Terminal volume of distribution in healthy human at 1000 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495426AUC (0 to infinity) in healthy human at 50 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571385Antibacterial activity against Enterobacter cloacae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495614AUC (0 to last) in human at 75 mg/kg, po measured on day 12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571576Antibacterial activity against Enterobacter cloacae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495576AUC (0 to last) in human at 1000 mg/kg, po measured on day 102010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495449Terminal phase elimination half-life in healthy human at 250 mg/kg, po administered single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495543Toxicity in human assessed as occurrence of somnolence at 750 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID570904Antibacterial activity against non-levofloxacin susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 64 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495451Terminal phase elimination half-life in healthy human at 1000 mg/kg, po administered single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571837Antibacterial activity against Enterobacter cloacae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 32 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495454Terminal volume of distribution in healthy human at 50 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571840Antibacterial activity against Proteus mirabilis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495536Toxicity in human assessed as occurrence of diarrhea at 750 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571145Antibacterial activity against Enterococcus faecalis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571144Antibacterial activity against Enterococcus faecalis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495546Cmax in human at 250 mg/kg, po measured on day 12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID570666Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus by CLSI M7-A7 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571875Antibacterial activity against Acinetobacter baumannii assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495534Toxicity in human assessed as occurrence of diarrhea at 250 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID570680Ratio of fAUC (0 to 24 hrs) in in vitro PK/PD model at 750 mg to MIC for Streptococcus pneumoniae2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495542Toxicity in human assessed as occurrence of somnolence at 500 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571835Antibacterial activity against Enterobacter cloacae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 8 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495418Toxicity in healthy human assessed as occurrence of ear pain at 25 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495492Ratio of fAUC to MIC90 for ciprofloxacin-resistant Streptococcus pneumoniae2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571384Antibacterial activity against Enterobacter cloacae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495374Toxicity in healthy human assessed as occurrence of pruritus at 1000 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495457Terminal volume of distribution in healthy human at 500 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495462Clearance in healthy human at 125 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495376Toxicity in healthy human assessed as occurrence of erythema at 25 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571375Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 32 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571846Antibacterial activity against Proteus mirabilis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 16 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495370Toxicity in healthy human assessed as occurrence of pruritus at 50 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495446Terminal phase elimination half-life in healthy human at 25 mg/kg, po administered single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495580Terminal half life in human at 1000 mg/kg, po measured on day 102010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID570686Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495491Ratio of fAUC to MIC90 for penicillin-resistant Streptococcus pneumoniae2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571349Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.03 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571367Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570930Antibacterial activity against methicillin-susceptible Staphylococcus epidermidis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495618AUC (0 to last) in human at 750 mg/kg, po measured on day 12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571151Antibacterial activity against Enterococcus faecalis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 128 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495524Toxicity in human assessed as occurrence of rashes at 250 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID570709Antibacterial activity against Levofloxacin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of <=0.008 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571350Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495522Toxicity in human assessed as occurrence of dermatitis at 750 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495597Oral clearance in human at 500 mg/kg measured on day 12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495464Clearance in healthy human at 500 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495373Toxicity in healthy human assessed as occurrence of pruritus at 500 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495406Toxicity in healthy human assessed as occurrence of pustular rashes at 125 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495466Clearance in healthy human at 1500 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571865Antibacterial activity against Stenotrophomonas maltophilia assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495525Toxicity in human assessed as occurrence of rashes at 1000 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571376Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 64 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495568Tmax in human at 1000 mg/kg, po measured on day 102010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495423Toxicity in healthy human assessed as occurrence of ear pain at 1000 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495397Toxicity in healthy human assessed as occurrence of abdominal pain at 25 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571871Antibacterial activity against Stenotrophomonas maltophilia assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 16 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495443Tmax in healthy human at 500 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571876Antibacterial activity against Acinetobacter baumannii assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571374Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 16 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571140Antibacterial activity against Enterococcus faecalis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.03 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571372Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495485Antimicrobial activity against ciprofloxacin-resistant Streptococcus pneumoniae2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495579Terminal half life in human at 500 mg/kg, po measured on day 102010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495540Toxicity in human assessed as occurrence of pollakiuria at 500 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571354Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495490Ratio of fAUC to MIC90 for penicillin-intermediate Streptococcus pneumoniae2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571362Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 256 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495415Toxicity in healthy human assessed as occurrence of nausea at 500 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495377Toxicity in healthy human assessed as occurrence of erythema at 50 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570888Antibacterial activity against Levofloxacin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.03 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495565Tmax in human at 750 mg/kg, po measured on day 12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571368Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571383Antibacterial activity against Enterobacter cloacae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495404Toxicity in healthy human assessed as occurrence of pustular rashes at 25 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495550Cmax in human at 500 mg/kg, po measured on day 102010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495487Antimicrobial activity against methicillin-resistant Staphylococcus aureus2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571851Antibacterial activity against Pseudomonas aeruginosa assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495382Toxicity in healthy human assessed as occurrence of erythema at 1500 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495564Tmax in human at 500 mg/kg, po measured on day 162010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495486Antimicrobial activity against methicillin-sensitive Staphylococcus aureus2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495453Terminal volume of distribution in healthy human at 25 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571379Antibacterial activity against Klebsiella oxytoca assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495590Clearance in human assessed as compound recovered in urine at 750 mg/kg, po measured on day 10 up to 24 hrs post dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495519Toxicity in human assessed as incidence of headache at 1000 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495587Clearance in human assessed as compound recovered in urine at 500 mg/kg, po measured on day 10 up to 24 hrs post dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID570897Antibacterial activity against non-levofloxacin susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571355Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495620AUC (0 to last) in human at 1000 mg/kg, po measured on day 12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID570670Antibacterial activity against penicillin-resistant Streptococcus pneumoniae by CLSI M7-A7 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495561Tmax in human at 250 mg/kg, po measured on day 102010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495430AUC (0 to infinity) in healthy human at 1000 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495392Toxicity in healthy human assessed as occurrence of oral hypoesthesia at 125 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495448Terminal phase elimination half-life in healthy human at 125 mg/kg, po administered single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571854Antibacterial activity against Pseudomonas aeruginosa assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570669Antibacterial activity against Streptococcus pneumoniae by CLSI M7-A7 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495414Toxicity in healthy human assessed as occurrence of nausea at 250 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495520Toxicity in human assessed as occurrence of dermatitis at 250 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495390Toxicity in healthy human assessed as occurrence of oral hypoesthesia at 25 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571109Antibacterial activity against methicillin-resistant Staphylococcus epidermidis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495547Cmax in human at 500 mg/kg, po measured on day 12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495467Renal clearance in healthy human at 25 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571346Antibacterial activity against Enterococcus faecium assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 64 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495552Cmax in human at 750 mg/kg, po measured on day 12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID570673Antibacterial activity against Enterobacteriaceae by CLSI M7-A7 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571147Antibacterial activity against Enterococcus faecalis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495558Tmax in human at 75 mg/kg, po measured on day 102010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID570677Ratio of fAUC (0 to 24 hrs) in in vitro PK/PD model at 750 mg to MIC for Staphylococcus aureus2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495470Renal clearance in healthy human at 250 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571146Antibacterial activity against Enterococcus faecalis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495541Toxicity in human assessed as occurrence of somnolence at 250 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID570691Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571861Antibacterial activity against Pseudomonas aeruginosa assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 256 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495479Clearance in healthy human assessed as recovery of unchanged drug in urine at 1000 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571378Antibacterial activity against Klebsiella oxytoca assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495606Renal clearance in human at 500 mg/kg, po measured on day 12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571352Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571112Antibacterial activity against methicillin-resistant Staphylococcus epidermidis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570704Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570695Antibacterial activity against Proteus mirabilis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 64 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495447Terminal phase elimination half-life in healthy human at 50 mg/kg, po administered single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495379Toxicity in healthy human assessed as occurrence of erythema at 250 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570889Antibacterial activity against Levofloxacin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495592Clearance in human assessed as compound recovered in urine at 1000mg/kg, po measured on day 10 up to 24 hrs post dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495496Ratio of fCmax to MIC90 for penicillin-sensitive Streptococcus pneumoniae2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495411Toxicity in healthy human assessed as occurrence of nausea at 25 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571857Antibacterial activity against Pseudomonas aeruginosa assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 16 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495407Toxicity in healthy human assessed as occurrence of pustular rashes at 250 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495554Cmax in human at 1000 mg/kg, po measured on day 12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID570682Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of <=0.008 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495381Toxicity in healthy human assessed as occurrence of erythema at 1000 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571868Antibacterial activity against Stenotrophomonas maltophilia assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570922Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 8 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495608Renal clearance in human at 500 mg/kg, po measured on day 162010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495548Cmax in human at 250 mg/kg, po measured on day 102010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571856Antibacterial activity against Pseudomonas aeruginosa assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 8 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495531Toxicity in human assessed as occurrence of pruritus at 250 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495477Clearance in healthy human assessed as recovery of unchanged drug in urine at 250 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571873Antibacterial activity against Stenotrophomonas maltophilia assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 64 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495475Clearance in healthy human assessed as recovery of unchanged drug in urine at 50 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495402Toxicity in healthy human assessed as occurrence of abdominal pain at 1000 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495616AUC (0 to last) in human at 250 mg/kg, po measured on day 12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495593Oral clearance in human at 75 mg/kg measured on day 12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495372Toxicity in healthy human assessed as occurrence of pruritus at 250 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495459Terminal volume of distribution in healthy human at 1500 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570902Antibacterial activity against non-levofloxacin susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 16 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570674Antibacterial activity against Pseudomonas aeruginosa by CLSI M7-A7 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570692Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 8 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495412Toxicity in healthy human assessed as occurrence of nausea at 50 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571142Antibacterial activity against Enterococcus faecalis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571369Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495461Clearance in healthy human at 50 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570679Ratio of fAUC (0 to 24 hrs) in in vitro PK/PD model at 750 mg to MIC for Staphylococcus epidermidis2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495438Cmax in healthy human at 1500 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570919Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570931Antibacterial activity against methicillin-susceptible Staphylococcus epidermidis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495626Oral clearance in human at 750 mg/kg measured on day 102010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495527Toxicity in human assessed as occurrence of abdominal pain at 500 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571364Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of <=0.015 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495368Toxicity in healthy human assessed as occurrence of contact dermatitis at 1500 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495363Toxicity in healthy human assessed as occurrence of contact dermatitis at 250 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570681Ratio of fAUC (0 to 24 hrs) in in vitro PK/PD model at 750 mg to MIC for penicillin-resistant Streptococcus pneumoniae2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570698Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495549Cmax in human at 75 mg/kg, po measured on day 102010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571855Antibacterial activity against Pseudomonas aeruginosa assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571341Antibacterial activity against Enterococcus faecium assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495385Toxicity in healthy human assessed as occurrence of headache at 125 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570678Ratio of fAUC (0 to 24 hrs) in in vitro PK/PD model at 750 mg to MIC for community-associated methicillin-resistant Staphylococcus aureus2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571119Antibacterial activity against Streptococcus pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.03 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570908Antibacterial activity against community-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570693Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 16 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495445Tmax in healthy human at 1500 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495478Clearance in healthy human assessed as recovery of unchanged drug in urine at 500 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571104Antibacterial activity against methicillin-susceptible Staphylococcus epidermidis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571373Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 8 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495365Toxicity in healthy human assessed as occurrence of contact dermatitis at 50 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495609Renal clearance in human at 750 mg/kg, po measured on day 12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571858Antibacterial activity against Pseudomonas aeruginosa assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 32 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495581Terminal half life in human at 250 mg/kg, po measured on day 102010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495595Oral clearance in human at 250 mg/kg measured on day 12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495560AUC (0 to last) in human at 500 mg/kg, po measured on day 162010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID570915Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.015 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571110Antibacterial activity against methicillin-resistant Staphylococcus epidermidis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495571AUC (0 to 24 hrs) in human at 250 mg/kg, po measured on day 12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571131Antibacterial activity against penicillin-resistant Streptococcus pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.03 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495493Ratio of fAUC to MIC90 for methicillin-sensitive Staphylococcus aureus2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495456Terminal volume of distribution in healthy human at 250 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495409Toxicity in healthy human assessed as occurrence of pustular rashes at 1000 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495391Toxicity in healthy human assessed as occurrence of oral hypoesthesia at 50 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570703Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571386Antibacterial activity against Enterobacter cloacae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495484Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571387Antibacterial activity against Enterobacter cloacae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570890Antibacterial activity against Levofloxacin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571337Antibacterial activity against Enterococcus faecium assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495452Terminal phase elimination half-life in healthy human at 1500 mg/kg, po administered single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571859Antibacterial activity against Pseudomonas aeruginosa assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 64 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495369Toxicity in healthy human assessed as occurrence of pruritus at 25 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495416Toxicity in healthy human assessed as occurrence of nausea at 1000 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495624AUC (0 to last) in human at 500 mg/kg, po measured on day 102010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495582Clearance in human assessed as compound recovered in urine at 75 mg/kg, po measured on day 1 up to 24 hrs post dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495362Toxicity in healthy human assessed as occurrence of contact dermatitis at 500 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571132Antibacterial activity against penicillin-resistant Streptococcus pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495539Toxicity in human assessed as occurrence of pollakiuria at 250 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571117Antibacterial activity against Streptococcus pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of <=0.008 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495628Ratio of fAUC (0 to 24 hrs) to MIC90 for Streptococcus pneumoniae2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571360Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 64 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570911Antibacterial activity against community-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570903Antibacterial activity against non-levofloxacin susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 32 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571143Antibacterial activity against Enterococcus faecalis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495622AUC (0 to 24 hrs) in human at 500 mg/kg, po measured on day 162010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571377Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 128 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571122Antibacterial activity against Streptococcus pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495613AUC (0 to 24 hrs) in human at 75 mg/kg, po measured on day 102010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571371Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495384Toxicity in healthy human assessed as occurrence of headache at 50 mg/kg, po2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495545Cmax in human at 75 mg/kg, po measured on day 12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495563Tmax in human at 500 mg/kg, po measured on day 102010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495555Cmax in human at 1000 mg/kg, po measured on day 102010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571336Antibacterial activity against Enterococcus faecium assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571356Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571877Antibacterial activity against Acinetobacter baumannii assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571344Antibacterial activity against Enterococcus faecium assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 16 ug/ml by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (39)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (7.69)29.6817
2010's30 (76.92)24.3611
2020's6 (15.38)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 40.91

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index40.91 (24.57)
Research Supply Index4.03 (2.92)
Research Growth Index4.94 (4.65)
Search Engine Demand Index57.52 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (40.91)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials15 (37.50%)5.53%
Reviews4 (10.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational1 (2.50%)0.25%
Other20 (50.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (13)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Multi-center, Randomized, Double-Blind, Parallel Comparative, Phase III Study to Evaluate the Efficacy and Safety of Intravenous Infusion of Nemonoxacin Versus Levofloxain in Treating Adult Patients With CAP [NCT02205112]Phase 3598 participants (Actual)Interventional2014-06-30Completed
A Randomized, Single-center, Placebo and Positive Control, 4-period and 4-crossover Clinical Study Evaluating the Effect of a Single-dose Oral Administration of Nemonoxacin Malate Capsule on QTc Intervals and Heart Rhythms of Healthy Subjects as Well as t [NCT03362853]Phase 148 participants (Actual)Interventional2012-06-25Completed
A Multi-Center, Open-Label, Single-Arm, Phase IV Study to Evaluate the Safety and Clinical Efficacy of Oral Administration With Nemonoxacin in Treating Elderly Patients With Community-Acquired Pneumonia [NCT05133752]Phase 4100 participants (Actual)Interventional2018-09-11Completed
Pharmacokinetics Study of Nemonoxacin Malate Capsules in Subjects With Moderate Impaired Hepatic Function [NCT02604498]Phase 120 participants (Actual)Interventional2016-04-14Completed
Pharmacokinetics Study of Nemonoxacin Malate Capsules in Subjects With Severe Impaired Renal Function [NCT02840812]Phase 124 participants (Anticipated)Interventional2017-04-05Recruiting
An Open-Label, Single-Arm, Multi-Center Study of TG-873870 for Treating Patients With Diabetic Foot Infections of Mild to Moderate Severity Associated With Gram-Positive Pathogens [NCT00685698]Phase 240 participants (Actual)Interventional2008-06-30Completed
Phase I Clinical Study on Oral Nemonoxacin Malate Capsules [NCT01395108]Phase 176 participants (Actual)Interventional2008-01-31Completed
A Randomized, Double-Blind, Comparative, Multi-Center Study of the Safety and Efficacy of TG-873870(Nemonoxacin) Versus Levofloxacin in Adult Patients With Community-Acquired Pneumonia (CAP) [NCT00434291]Phase 2264 participants (Anticipated)Interventional2006-12-31Completed
A Randomized, Double-Blind, Comparative, Multi-Center Study of the Safety and Efficacy of TG-873870(Nemonoxacin) Versus Levofloxacin in Adult Patients With Community-Acquired Pneumonia (CAP) [NCT01529476]Phase 3540 participants (Actual)Interventional2011-04-30Completed
A Phase I Clinical Study of Nemonoxacin Malate Sodium Chloride Injection Administered by Intravenous Infusion [NCT01529957]Phase 1176 participants (Actual)Interventional2008-09-30Completed
A Multi-center, Randomized, Double-blind, Double-dummy Parallel-controlled Phase II Clinical Study to Assess the Efficacy and Safety of Nemonoxacin Malate in Treating Adult Patients With Community-acquired Pneumonia (CAP) [NCT01537250]Phase 2192 participants (Actual)Interventional2009-08-31Completed
A Multi-Center, Randomized, Double-Blind, Parallel Comparative, Phase II Study to Evaluate the Efficacy and Safety of Intravenous Infusion With Nemonoxacin Versus Moxifloxacin in Treating Adult Patients With Community-Acquired Pneumonia (CAP) [NCT01944774]Phase 2207 participants (Actual)Interventional2013-03-31Completed
An International, Multicenter, Randomized, Double-blind, Double-dummy, Two-way, Parallel Group, Controlled Study to Compare the Efficacy and Safety of Intravenous and Oral Nemonoxacin Versus Tavanic® in Adult Patients With Community-acquired Pneumonia [NCT03551210]Phase 3342 participants (Actual)Interventional2016-05-04Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00685698 (19) [back to overview]Clinical Success (at End of Treatment/Early Termination)
NCT00685698 (19) [back to overview]Clinical Success (in ITT Population)
NCT00685698 (19) [back to overview]Clinical Success (in PP Population)
NCT00685698 (19) [back to overview]Microbiological Success Rate
NCT00685698 (19) [back to overview]Total Wound Score (at End of Treatment/ Early Termination in ITT Population)
NCT00685698 (19) [back to overview]Total Wound Score (at End of Treatment/ Early Termination in PP Population)
NCT00685698 (19) [back to overview]Total Wound Score (at Test of Cure in ITT Population)
NCT00685698 (19) [back to overview]Total Wound Score (at Test of Cure in PP Population)
NCT00685698 (19) [back to overview]Diabetic Foot Assessment (PEDIS) Shifts From Baseline at End of Treatment/Early Termination in ITT Population
NCT00685698 (19) [back to overview]Diabetic Foot Assessment (PEDIS) Shifts From Baseline at End of Treatment/Early Termination in PP Population
NCT00685698 (19) [back to overview]Diabetic Foot Assessment (PEDIS) Shifts From Baseline at Test of Cure in ITT Population
NCT00685698 (19) [back to overview]Diabetic Foot Assessment (PEDIS) Shifts From Baseline at Test of Cure in PP Population
NCT00685698 (19) [back to overview]Need for Surgery, Hospitalisation and Non-Study Antibiotic Therapy for Diabetic Foot Infection During Study (in ITT Population)
NCT00685698 (19) [back to overview]Need for Surgery, Hospitalisation and Non-Study Antibiotic Therapy for Diabetic Foot Infection During Study (in ITT Population)
NCT00685698 (19) [back to overview]Need for Surgery, Hospitalisation and Non-Study Antibiotic Therapy for Diabetic Foot Infection During Study (in PP Population)
NCT00685698 (19) [back to overview]Need for Surgery, Hospitalisation and Non-Study Antibiotic Therapy for Diabetic Foot Infection During Study (in PP Population)
NCT00685698 (19) [back to overview]Per-Pathogen Clinical Response (at End of Treatment/Early Termination)
NCT00685698 (19) [back to overview]Per-Pathogen Clinical Responses (at Test of Cure)
NCT00685698 (19) [back to overview]Per-Pathogen Microbiological Responses
NCT01944774 (12) [back to overview]Difference in the Clinical Cure Rate of Two Doses of Intravenously Infused Nemonoxacin Malate Sodium Chloride Injection at Visit 3 in the CE Population
NCT01944774 (12) [back to overview]Difference in the Clinical Cure Rate of Two Doses of Intravenously Infused Nemonoxacin Malate Sodium Chloride Injection at Visit 3 in the mITT Population
NCT01944774 (12) [back to overview]Difference in the Clinical Cure Rate of Two Doses of Intravenously Infused Nemonoxacin Malate Sodium Chloride Injection at Visit 4 in the Clinically Evaluable (CE) Population
NCT01944774 (12) [back to overview]Difference in the Clinical Cure Rate of Two Doses of Intravenously Infused Nemonoxacin Malate Sodium Chloride Injection at Visit 4 in the mITT Population
NCT01944774 (12) [back to overview]Subject Number for Microbiologically Cured and Failure at Visit 3 in b-mITT (Bacteriological mITT) Population
NCT01944774 (12) [back to overview]Subject Number for Microbiologically Cured and Failure at Visit 3 in BE (Bacteriological Evaluable) Population
NCT01944774 (12) [back to overview]Subject Number for Microbiologically Cured and Failure at Visit 4 in b-mITT (Bacteriological mITT) Population
NCT01944774 (12) [back to overview]Subject Number for Microbiologically Cured and Failure at Visit 4 in BE (Bacteriological Evaluable) Population
NCT01944774 (12) [back to overview]Subject Number of Success and Failure in Overall Efficacy at Visit 3 in b-mITT (Bacteriological mITT) Population
NCT01944774 (12) [back to overview]Subject Number of Success and Failure in Overall Efficacy at Visit 3 in BE (Bacteriological Evaluable) Population
NCT01944774 (12) [back to overview]Subject Number of Success and Failure in Overall Efficacy at Visit 4 in b-mITT (Bacteriological mITT) Population
NCT01944774 (12) [back to overview]Subject Number of Success and Failure in Overall Efficacy at Visit 4 in BE (Bacteriological Evaluable) Population
NCT03551210 (10) [back to overview]Number of Patients Required for Other Antibiotic Treatment
NCT03551210 (10) [back to overview]Number of Patients With Infection Relapse
NCT03551210 (10) [back to overview]Terminal Elimination Half-life (T1/2) of Nemonoxacin
NCT03551210 (10) [back to overview]Time to Switch Therapy From Intravenous to Oral Therapy
NCT03551210 (10) [back to overview]Volume of Distribution at Steady State (Vss) of Nemonoxacin
NCT03551210 (10) [back to overview]Сlearance (CL) of Nemonoxacin
NCT03551210 (10) [back to overview]Area Under the Concentration-time Curve (AUC) of Nemonoxacin
NCT03551210 (10) [back to overview]Nemnoxacin Concentration Changes
NCT03551210 (10) [back to overview]Number of Patients With Microbiological Success
NCT03551210 (10) [back to overview]Number of Patients With Clinical Success as Judged by the Investigator

Clinical Success (at End of Treatment/Early Termination)

"Clinical Success~Resolution is defined as total resolution of all pretreatment clinically significant signs and symptoms of infection and no development of any systemic evidence of infection.~Improvement is defined as resolution of more than two, but not all, pretreatment clinical signs and symptoms, or partial resolution of all clinical signs and symptoms relative to the baseline assessment, with no further need for antibiotic therapy, and no need for infection-related surgical interventions." (NCT00685698)
Timeframe: End of Treatment/Early Termination Visit; 7±1, 14±1, 21±1 or 28±1 days after Baseline (Day 1)

Interventionpercentage of participants (Number)
Nemonoxacin (ITT Population at EOT/ET)100.0
Nemonoxacin (PP Population at EOT/ET)100.0

[back to top]

Clinical Success (in ITT Population)

"Clinical Success~Resolution is defined as total resolution of all pretreatment clinically significant signs and symptoms of infection and no development of any systemic evidence of infection.~Improvement is defined as resolution of more than two, but not all, pretreatment clinical signs and symptoms, or partial resolution of all clinical signs and symptoms relative to the baseline assessment, with no further need for antibiotic therapy, and no need for infection-related surgical interventions." (NCT00685698)
Timeframe: Test of Cure Visit, 12±2 days after End of Treatment Visit/Early Termination

Interventionpercentage of participants (Number)
Nemonoxacin95.7

[back to top]

Clinical Success (in PP Population)

"Clinical Success~Resolution is defined as total resolution of all pretreatment clinically significant signs and symptoms of infection and no development of any systemic evidence of infection.~Improvement is defined as resolution of more than two, but not all, pretreatment clinical signs and symptoms, or partial resolution of all clinical signs and symptoms relative to the baseline assessment, with no further need for antibiotic therapy, and no need for infection-related surgical interventions." (NCT00685698)
Timeframe: Test of Cure Visit, 12±2 days after End of Treatment Visit/Early Termination

Interventionpercentage of participants (Number)
Nemonoxacin94.7

[back to top]

Microbiological Success Rate

"Microbiological Success~Eradicated, defined as absence of the original pathogen(s) from a repeat culture of the original infection site performed at the TOC visit.~Presumed Eradicated, defined as meeting the definition for Clinical Success at the TOC visit, but tissue sample could be obtained for culture from the original infection site.~TOC=Test of Cure" (NCT00685698)
Timeframe: Test of Cure Visit, 12±2 days after End of Treatment Visit/Early Termination

Interventionpercentage of participants (Number)
Nemonoxacin (ITT Population at Test of Cure Visit)82.6
Nemonoxacin (PP Population at Test of Cure Visit)89.5

[back to top]

Total Wound Score (at End of Treatment/ Early Termination in ITT Population)

The Diabetic Foot Infection (DFI) Wound Scores will be used to evaluate the wound assessment at baseline and End of Treatment/ Early Termination visits. The wound composite score was based on combining the general wound parameters (signs and symptoms of infection), and wound measurements (length, width, depth). Each wound parameter was assigned a score based on severity, with higher scores defining greater severity. For wound measurements and undermining, larger measurements received higher scores. The minimum and maximum score are 3 and 49, respectively. (NCT00685698)
Timeframe: Visit 1 (Baseline); End of Treatment/Early Termination Visit; 7±1, 14±1, 21±1 or 28±1 days after Baseline (Day 1)

Interventionscores on a scale (Mean)
Nemonoxacin (at Baseline, ITT Population)16.9
Nemonoxacin (at EOT/ET Visit, ITT Population)7.2
Nemonoxacin (Change From Baseline to EOT/ET Visit)-9.6

[back to top]

Total Wound Score (at End of Treatment/ Early Termination in PP Population)

The Diabetic Foot Infection (DFI) Wound Scores will be used to evaluate the wound assessment at baseline and Test of Cure visits. The wound composite score was based on combining the general wound parameters (signs and symptoms of infection), and wound measurements (length, width, depth). Each wound parameter was assigned a score based on severity, with higher scores defining greater severity. For wound measurements and undermining, larger measurements received higher scores. The minimum and maximum score are 3 and 49, respectively. (NCT00685698)
Timeframe: Visit 1 (Baseline); End of Treatment/Early Termination Visit; 7±1, 14±1, 21±1 or 28±1 days after Baseline (Day 1)

Interventionscores on a scale (Mean)
Nemonoxacin (at Baseline, PP Population)18.2
Nemonoxacin (at EOT/ET Visit, PP Population)6.2
Nemonoxacin (Change From Baseline to EOT/ET Visit)-12.1

[back to top]

Total Wound Score (at Test of Cure in ITT Population)

The Diabetic Foot Infection (DFI) Wound Scores will be used to evaluate the wound assessment at baseline and Test of Cure visits. The wound composite score was based on combining the general wound parameters (signs and symptoms of infection), and wound measurements (length, width, depth). Each wound parameter was assigned a score based on severity, with higher scores defining greater severity. For wound measurements and undermining, larger measurements received higher scores. The minimum and maximum score are 3 and 49, respectively. (NCT00685698)
Timeframe: Visit 1 (Baseline); Test of Cure Visit, 12±2 days after End of Treatment Visit/Early Termination

Interventionscores on a scale (Mean)
Nemonoxacin (at Baseline, ITT Population)16.9
Nemonoxacin (at Test of Cure Visit, ITT Population)6.0
Nemonoxacin (Change From Baseline to Test of Cure Visit)-11.2

[back to top]

Total Wound Score (at Test of Cure in PP Population)

The Diabetic Foot Infection (DFI) Wound Scores will be used to evaluate the wound assessment at baseline and Test of Cure visits. The wound composite score was based on combining the general wound parameters (signs and symptoms of infection), and wound measurements (length, width, depth). Each wound parameter was assigned a score based on severity, with higher scores defining greater severity. For wound measurements and undermining, larger measurements received higher scores. The minimum and maximum score are 3 and 49, respectively. (NCT00685698)
Timeframe: Visit 1 (Baseline); Test of Cure Visit, 12±2 days after End of Treatment Visit/Early Termination

Interventionscores on a scale (Mean)
Nemonoxacin (at Baseline, PP Population)18.2
Nemonoxacin (at Test of Cure Visit, PP Population)5.0
Nemonoxacin (Change From Baseline to Test of Cure Visit)-12.9

[back to top]

Diabetic Foot Assessment (PEDIS) Shifts From Baseline at End of Treatment/Early Termination in ITT Population

The number of patients within each of the PEDIS grading categories (uninfected, mild, moderate and severe) at baseline and End of Treatment/Early Termination. (NCT00685698)
Timeframe: End of Treatment/Early Termination Visit; 7±1, 14±1, 21±1 or 28±1 days after Baseline (Day 1)

Interventionparticipants (Number)
Uninfected to UninfectedUninfected to MildUninfected to ModerateUninfected to SevereMild to UninfectedMild to MildMild to ModerateMild to SevereModerate to UninfectedModerate to MildModerate to ModerateModerate to SevereSevere to UninfectedSevere to MildSevere to ModerateSevere to Severe
Nemonoxacin00008400125300000

[back to top]

Diabetic Foot Assessment (PEDIS) Shifts From Baseline at End of Treatment/Early Termination in PP Population

The number of patients within each of the PEDIS grading categories (uninfected, mild, moderate and severe) at baseline and End of Treatment/Early Termination. (NCT00685698)
Timeframe: End of Treatment/Early Termination Visit; 7±1, 14±1, 21±1 or 28±1 days after Baseline (Day 1)

Interventionparticipants (Number)
Uninfected to UninfectedUninfected to MildUninfected to ModerateUninfected to SevereMild to UninfectedMild to MildMild to ModerateMild to SevereModerate to UninfectedModerate to MildModerate to ModerateModerate to SevereSevere to UninfectedSevere to MildSevere to ModerateSevere to Severe
Nemonoxacin0000610092200000

[back to top]

Diabetic Foot Assessment (PEDIS) Shifts From Baseline at Test of Cure in ITT Population

The number of patients within each of the PEDIS grading categories (uninfected, mild, moderate and severe) at baseline and Test of Cure. (NCT00685698)
Timeframe: Test of Cure Visit, 12±2 days after End of Treatment Visit/Early Termination

Interventionparticipants (Number)
Uninfected to UninfectedUninfected to MildUninfected to ModerateUninfected to SevereMild to UninfectedMild to MildMild to ModerateMild to SevereModerate to UninfectedModerate to MildModerate to ModerateModerate to SevereSevere to UninfectedSevere to MildSevere to ModerateSevere to Severe
Nemonoxacin00008200153000000

[back to top]

Diabetic Foot Assessment (PEDIS) Shifts From Baseline at Test of Cure in PP Population

The number of patients within each of the PEDIS grading categories (uninfected, mild, moderate and severe) at baseline and Test of Cure. (NCT00685698)
Timeframe: Test of Cure Visit, 12±2 days after End of Treatment Visit/Early Termination

Interventionparticipants (Number)
Uninfected to UninfectedUninfected to MildUninfected to ModerateUninfected to SevereMild to UninfectedMild to MildMild to ModerateMild to SevereModerate to UninfectedModerate to MildModerate to ModerateModerate to SevereSevere to UninfectedSevere to MildSevere to ModerateSevere to Severe
Nemonoxacin00006100111000000

[back to top]

Need for Surgery, Hospitalisation and Non-Study Antibiotic Therapy for Diabetic Foot Infection During Study (in ITT Population)

Results in relation to the need for surgery, hospitalization, new and/or additional non-study antibiotic therapy for failure of initial oral therapy at End of Treatment/Early Termination. (NCT00685698)
Timeframe: End of Treatment/Early Termination Visit; 7±1, 14±1, 21±1 or 28±1 days after Baseline (Day 1)

Interventionparticipants (Number)
Surgery Required for DFI During StudyHospitalisation Required for DFI During StudyNew or Additional Antibiotic Therapy Required
Nemonoxacin113

[back to top]

Need for Surgery, Hospitalisation and Non-Study Antibiotic Therapy for Diabetic Foot Infection During Study (in ITT Population)

Results in relation to the need for surgery, hospitalization, new and/or additional non-study antibiotic therapy for failure of initial oral therapy at Test of Cure. (NCT00685698)
Timeframe: Test of Cure Visit, 12±2 days after End of Treatment Visit/Early Termination

Interventionparticipants (Number)
Surgery Required for DFI During StudyHospitalisation Required for DFI During StudyNew or Additional Antibiotic Therapy Required
Nemonoxacin113

[back to top]

Need for Surgery, Hospitalisation and Non-Study Antibiotic Therapy for Diabetic Foot Infection During Study (in PP Population)

Results in relation to the need for surgery, hospitalization, new and/or additional non-study antibiotic therapy for failure of initial oral therapy at End of Treatment/Early Termination. (NCT00685698)
Timeframe: End of Treatment/Early Termination Visit; 7±1, 14±1, 21±1 or 28±1 days after Baseline (Day 1)

Interventionparticipants (Number)
Surgery Required for DFI During StudyHospitalisation Required for DFI During StudyNew or Additional Antibiotic Therapy Required
Nemonoxacin000

[back to top]

Need for Surgery, Hospitalisation and Non-Study Antibiotic Therapy for Diabetic Foot Infection During Study (in PP Population)

Results in relation to the need for surgery, hospitalization, new and/or additional non-study antibiotic therapy for failure of initial oral therapy at Test of Cure. (NCT00685698)
Timeframe: Test of Cure Visit, 12±2 days after End of Treatment Visit/Early Termination

Interventionparticipants (Number)
Surgery Required for DFI During StudyHospitalisation Required for DFI During StudyNew or Additional Antibiotic Therapy Required
Nemonoxacin001

[back to top]

Per-Pathogen Clinical Response (at End of Treatment/Early Termination)

Clinical responses were assessed on a per-pathogen basis for the most frequently isolated pathogens at baseline (i.e., present in four or more patients), including MRSA. Clinical Responses were assessed at at End of Treatment/Early Termination within each of the ITT and PP populations. Insufficient numbers prevented reporting Clinical Success rates for Streptococcus pyogenes in the PP population. (NCT00685698)
Timeframe: End of Treatment/Early Termination Visit; 7±1, 14±1, 21±1 or 28±1 days after Baseline (Day 1)

,
Interventionpercentage of participants (Number)
Staphylococcus aureus (in ITT population)Escherichia coli (in ITT population)Enterococcus faecalis (in ITT population)Streptococcus agalactiae (in ITT population)Streptococcus pyogenes (in ITT population)
Nemonoxacin (ITT Population at EOT/ET)100.0100.0100.0100.0100.0
Nemonoxacin (PP Population at EOT/ET)100.0100.0100.0100.0NA

[back to top]

Per-Pathogen Clinical Responses (at Test of Cure)

Clinical responses were assessed on a per-pathogen basis for the most frequently isolated pathogens at baseline (i.e., present in four or more patients), including MRSA. Clinical Responses were assessed at Test of Cure visit within each of the ITT and PP populations. Insufficient numbers prevented reporting Clinical Success rates for Streptococcus pyogenes in the PP population. (NCT00685698)
Timeframe: Test of Cure Visit, 12±2 days after End of Treatment Visit/Early Termination

,
Interventionpercentage of participants (Number)
Staphylococcus aureusEscherichia coli (in ITT population)Enterococcus faecalis (in ITT population)Streptococcus agalactiae (in ITT population)Streptococcus pyogenes (in ITT population)
Nemonoxacin (ITT Population at Test of Cure Visit)100.0100.0100.0100.0100.0
Nemonoxacin (PP Population at Test of Cure Visit)100.0100.0100.0100.0NA

[back to top]

Per-Pathogen Microbiological Responses

Microbiological responses were assessed on a per-pathogen basis for the most frequently isolated pathogens at baseline (i.e., present in four or more patients), including MRSA. Microbiological Responses were assessed at Test of Cure visit within each of the ITT and PP populations. Insufficient numbers prevented reporting Microbiological Success rates for Streptococcus pyogenes in the PP population. (NCT00685698)
Timeframe: Test of Cure Visit, 12±2 days after End of Treatment Visit/Early Termination

,
Interventionpercentage of participants (Number)
Staphylococcus aureus (in ITT population)Escherichia coli (in ITT population)Enterococcus faecalis (in ITT population)Streptococcus agalactiae (in ITT population)Streptococcus pyogenes (in ITT population)
Nemonoxacin (ITT Population at Test of Cure Visit)93.366.775.0100.0100.0
Nemonoxacin (PP Population at Test of Cure Visit)100.075.075.0100.0NA

[back to top]

Difference in the Clinical Cure Rate of Two Doses of Intravenously Infused Nemonoxacin Malate Sodium Chloride Injection at Visit 3 in the CE Population

The primary efficacy endpoint of this study was to evaluate whether the clinical cure rate of Nemonoxacin malate sodium chloride is non-inferior to that of Moxifloxacin at visit 3 in the CE population. At visit 3, the Investigator would assess changes in the symptoms/signs/laboratory tests and chest X-rays/or CT scans associated with this infection, and determined the clinical efficacy in the subjects. The clinical efficacy of the study group and the control group was calculated according to the proportion and percentage of overall clinically cured and clinically ineffective patients in the treatment groups. If the lower limit of the 90% confidence interval for the difference in the clinical cure rate between the study drug and the control drug was larger than -15%, it would be established that the efficacy of Nemonoxacin malate sodium chloride injection was not inferior to that of Moxifloxacin Hydrochloride Sodium Chloride Injection in the treatment of moderate to severe adult CAP. (NCT01944774)
Timeframe: Visit 1 (baseline, day -1~1) to Visit 3 (Within 24 hours after stopping the drug)

,,
Interventionparticipants (Number)
SuccessFailNot evaluable
Moxifloxacin 400 mg5622
Nemonoxacin 500 mg5841
Nemonoxacin 650 mg5630

[back to top]

Difference in the Clinical Cure Rate of Two Doses of Intravenously Infused Nemonoxacin Malate Sodium Chloride Injection at Visit 3 in the mITT Population

The primary efficacy endpoint of this study was to evaluate whether the clinical cure rate of Nemonoxacin malate sodium chloride is non-inferior to that of Moxifloxacin at visit 3 in the mITT population. At visit 3, the Investigator would assess changes in the symptoms/signs/laboratory tests and chest X-rays/or CT scans associated with this infection, and determined the clinical efficacy in the subjects. The clinical efficacy of the study group and the control group was calculated according to the proportion and percentage of overall clinically cured and clinically ineffective patients in the treatment groups. If the lower limit of the 90% confidence interval for the difference in the clinical cure rate between the study drug and the control drug was larger than -15%, it would be established that the efficacy of Nemonoxacin malate sodium chloride injection was not inferior to that of Moxifloxacin Hydrochloride Sodium Chloride Injection in the treatment of moderate to severe adult CAP. (NCT01944774)
Timeframe: Visit 1 (baseline, day -1~1) to Visit 3 (Within 24 hours after stopping the drug)

,,
Interventionparticipants (Number)
SuccessFailNot evaluable
Moxifloxacin 400 mg5923
Nemonoxacin 500 mg6142
Nemonoxacin 650 mg6040

[back to top]

Difference in the Clinical Cure Rate of Two Doses of Intravenously Infused Nemonoxacin Malate Sodium Chloride Injection at Visit 4 in the Clinically Evaluable (CE) Population

The primary efficacy endpoint of this study was to evaluate whether the clinical cure rate of Nemonoxacin malate sodium chloride is non-inferior to that of Moxifloxacin at visit 4 in the CE population. At visit 4, the Investigator would assess changes in the symptoms/signs/laboratory tests and chest X-rays/or CT scans associated with this infection, and determined the clinical efficacy in the subjects. The clinical efficacy of the study group and the control group was calculated according to the proportion and percentage of overall clinically cured and clinically ineffective patients in the treatment groups. If the lower limit of the 90% confidence interval for the difference in the clinical cure rate between the study drug and the control drug was larger than -15%, it would be established that the efficacy of Nemonoxacin malate sodium chloride injection was not inferior to that of Moxifloxacin Hydrochloride Sodium Chloride Injection in the treatment of moderate to severe adult CAP. (NCT01944774)
Timeframe: Visit 1 (baseline, day -1~1) to Visit 4 (7-14 days after stopping the drug)

,,
Interventionparticipants (Number)
SuccessNot evaluable
Moxifloxacin 400 mg582
Nemonoxacin 500 mg567
Nemonoxacin 650 mg563

[back to top]

Difference in the Clinical Cure Rate of Two Doses of Intravenously Infused Nemonoxacin Malate Sodium Chloride Injection at Visit 4 in the mITT Population

The primary efficacy endpoint of this study was to evaluate whether the clinical cure rate of Nemonoxacin malate sodium chloride is non-inferior to that of Moxifloxacin at visit 4 in the mITT population. At visit 4, the Investigator would assess changes in the symptoms/signs/laboratory tests and chest X-rays/or CT scans associated with this infection, and determined the clinical efficacy in the subjects. The clinical efficacy of the study group and the control group was calculated according to the proportion and percentage of overall clinically cured and clinically ineffective patients in the treatment groups. If the lower limit of the 90% confidence interval for the difference in the clinical cure rate between the study drug and the control drug was larger than -15%, it would be established that the efficacy of Nemonoxacin malate sodium chloride injection was not inferior to that of Moxifloxacin Hydrochloride Sodium Chloride Injection in the treatment of moderate to severe adult CAP. (NCT01944774)
Timeframe: Visit 1 (baseline, day -1~1) to Visit 4 (7-14 days after stopping the drug)

,,
Interventionparticipants (Number)
SuccessFailNot evaluable
Moxifloxacin 400 mg5923
Nemonoxacin 500 mg6070
Nemonoxacin 650 mg5842

[back to top]

Subject Number for Microbiologically Cured and Failure at Visit 3 in b-mITT (Bacteriological mITT) Population

"Microbiological efficacy at visits 3 would be determined by assessing the identification results from the central laboratory. Subjects must satisfy at least one of the following in order to be evaluated for the microbiological efficacy:~Subjects whose respiratory culture from visit 1 was positive;~Subjects whose blood culture from visit 1 was positive.~The microbiological efficacy at Visit 3 and treatment group (determined by each subject) was determined by the number and percentage of microbiological success subjects. The difference in bacteriological success between Nemonoxacin malate sodium chloride injection and Moxifloxacin Hydrochloride Sodium Chloride Injection was tested using the logistic regression model." (NCT01944774)
Timeframe: Visit 1 (baseline, day -1~1) to Visit 3 (Within 24 hours after stopping the drug)

,,
Interventionparticipants (Number)
SuccessFailureNot evaluable
Moxifloxacin 400 mg1601
Nemonoxacin 500 mg2220
Nemonoxacin 650 mg1810

[back to top]

Subject Number for Microbiologically Cured and Failure at Visit 3 in BE (Bacteriological Evaluable) Population

"Microbiological efficacy at visits 3 would be determined by assessing the identification results from the central laboratory. Subjects must satisfy at least one of the following in order to be evaluated for the microbiological efficacy:~Subjects whose respiratory culture from visit 1 was positive;~Subjects whose blood culture from visit 1 was positive.~The microbiological efficacy at Visit 3 and treatment group (determined by each subject) was determined by the number and percentage of microbiological success subjects. The difference in bacteriological success between Nemonoxacin malate sodium chloride injection and Moxifloxacin Hydrochloride Sodium Chloride Injection was tested using the logistic regression model." (NCT01944774)
Timeframe: Visit 1 (baseline, day -1~1) to Visit 3 (Within 24 hours after stopping the drug)

,,
Interventionparticipants (Number)
SuccessFailureNot evaluable
Moxifloxacin 400 mg1600
Nemonoxacin 500 mg2120
Nemonoxacin 650 mg1810

[back to top]

Subject Number for Microbiologically Cured and Failure at Visit 4 in b-mITT (Bacteriological mITT) Population

"Microbiological efficacy at visits 4 would be determined by assessing the identification results from the central laboratory. Subjects must satisfy at least one of the following in order to be evaluated for the microbiological efficacy:~Subjects whose respiratory culture from visit 1 was positive;~Subjects whose blood culture from visit 1 was positive.~The microbiological efficacy at Visit 4 and treatment group (determined by each subject) was determined by the number and percentage of microbiological success subjects. The difference in bacteriological success between Nemonoxacin malate sodium chloride injection and Moxifloxacin Hydrochloride Sodium Chloride Injection was tested using the logistic regression model." (NCT01944774)
Timeframe: Visit 1 (baseline, day -1~1) to Visit 4 (7-14 days after stopping the drug)

,,
Interventionparticipants (Number)
SuccessFailureNot evaluable
Moxifloxacin 400 mg1601
Nemonoxacin 500 mg2130
Nemonoxacin 650 mg1711

[back to top]

Subject Number for Microbiologically Cured and Failure at Visit 4 in BE (Bacteriological Evaluable) Population

"Microbiological efficacy at visits 4 would be determined by assessing the identification results from the central laboratory. Subjects must satisfy at least one of the following in order to be evaluated for the microbiological efficacy:~Subjects whose respiratory culture from visit 1 was positive;~Subjects whose blood culture from visit 1 was positive.~The microbiological efficacy at Visit 4 and treatment group (determined by each subject) was determined by the number and percentage of microbiological success subjects. The difference in bacteriological success between Nemonoxacin malate sodium chloride injection and Moxifloxacin Hydrochloride Sodium Chloride Injection was tested using the logistic regression model." (NCT01944774)
Timeframe: Visit 1 (baseline, day -1~1) to Visit 4 (7-14 days after stopping the drug)

,,
Interventionparticipants (Number)
SuccessFailureNot evaluable
Moxifloxacin 400 mg1501
Nemonoxacin 500 mg2030
Nemonoxacin 650 mg1711

[back to top]

Subject Number of Success and Failure in Overall Efficacy at Visit 3 in b-mITT (Bacteriological mITT) Population

Only subjects whose bacterial culture from visit 1 was positive would be evaluated for the overall efficacy. The overall efficacy (cured or ineffective) at Visit 3 and treatment group (determined by each subject) was determined by the number and percentage of subjects. The difference in bacteriological success between Nemonoxacin malate sodium chloride injection and Moxifloxacin Hydrochloride Sodium Chloride Injection was tested using the logistic regression model. (NCT01944774)
Timeframe: Visit 1 (baseline, day -1~1) to Visit 3 (Within 24 hours after stopping the drug)

,,
Interventionparticipants (Number)
SuccessFailureUnevaluable
Moxifloxacin 400 mg1511
Nemonoxacin 500 mg2220
Nemonoxacin 650 mg1720

[back to top]

Subject Number of Success and Failure in Overall Efficacy at Visit 3 in BE (Bacteriological Evaluable) Population

Only subjects whose bacterial culture from visit 1 was positive would be evaluated for the overall efficacy. The overall efficacy (cured or ineffective) at Visit 3 and treatment group (determined by each subject) was determined by the number and percentage of subjects. The difference in bacteriological success between Nemonoxacin malate sodium chloride injection and Moxifloxacin Hydrochloride Sodium Chloride Injection was tested using the logistic regression model. (NCT01944774)
Timeframe: Visit 1 (baseline, day -1~1) to Visit 3 (Within 24 hours after stopping the drug)

,,
Interventionparticipants (Number)
SuccessFailure
Moxifloxacin 400 mg151
Nemonoxacin 500 mg212
Nemonoxacin 650 mg172

[back to top]

Subject Number of Success and Failure in Overall Efficacy at Visit 4 in b-mITT (Bacteriological mITT) Population

Only subjects whose bacterial culture from visit 1 was positive would be evaluated for the overall efficacy. The overall efficacy (cured or ineffective) at Visit 4 and treatment group (determined by each subject) was determined by the number and percentage of subjects. The difference in bacteriological success between Nemonoxacin malate sodium chloride injection and Moxifloxacin Hydrochloride Sodium Chloride Injection was tested using the logistic regression model. (NCT01944774)
Timeframe: Visit 1 (baseline, day -1~1) to Visit 4 (7-14 days after stopping the drug)

,,
Interventionparticipants (Number)
SuccessFailure
Moxifloxacin 400 mg161
Nemonoxacin 500 mg213
Nemonoxacin 650 mg172

[back to top]

Subject Number of Success and Failure in Overall Efficacy at Visit 4 in BE (Bacteriological Evaluable) Population

Only subjects whose bacterial culture from visit 1 was positive would be evaluated for the overall efficacy. The overall efficacy (cured or ineffective) at Visit 4 and treatment group (determined by each subject) was determined by the number and percentage of subjects. The difference in bacteriological success between Nemonoxacin malate sodium chloride injection and Moxifloxacin Hydrochloride Sodium Chloride Injection was tested using the logistic regression model. (NCT01944774)
Timeframe: Visit 1 (baseline, day -1~1) to Visit 4 (7-14 days after stopping the drug)

,,
Interventionparticipants (Number)
SuccessFailure
Moxifloxacin 400 mg151
Nemonoxacin 500 mg203
Nemonoxacin 650 mg172

[back to top]

Number of Patients Required for Other Antibiotic Treatment

(NCT03551210)
Timeframe: Up to 21-23 days after last dose

InterventionParticipants (Count of Participants)
Nemonoxacin2
Tavanic®5

[back to top]

Number of Patients With Infection Relapse

(NCT03551210)
Timeframe: Visit 5 (within 21-23 days after last dose)

InterventionParticipants (Count of Participants)
Nemonoxacin0
Tavanic®2

[back to top]

Terminal Elimination Half-life (T1/2) of Nemonoxacin

Terminal elimination half-life of Nemonoxacin (NCT03551210)
Timeframe: Day 1 pre-dose and 0, 0.5, 2.5, 4, 6, 12, 16 and 22.5 (= Day 2 pre-dose) hrs after the end of first infusion on Day 1 of treatment

Interventionhours (Mean)
Nemonoxacin7.04

[back to top]

Time to Switch Therapy From Intravenous to Oral Therapy

(NCT03551210)
Timeframe: Up to Visit 2 (day 4/8 ot treatment)

Interventiondays (Median)
Nemonoxacin4
Tavanic®4

[back to top]

Volume of Distribution at Steady State (Vss) of Nemonoxacin

Volume of distribution at steady state of Nemonoxacin (NCT03551210)
Timeframe: Day 1 pre-dose and 0, 0.5, 2.5, 4, 6, 12, 16 and 22.5 (= Day 2 pre-dose) hrs after the end of first infusion on Day 1 of treatment

Interventionliters (Mean)
Nemonoxacin123.76

[back to top]

Сlearance (CL) of Nemonoxacin

Total systemic clearance of Nemonoxacin (NCT03551210)
Timeframe: Day 1 pre-dose and 0, 0.5, 2.5, 4, 6, 12, 16 and 22.5 (= Day 2 pre-dose) hrs after the end of first infusion on Day 1 of treatment

Interventionml/min (Mean)
Nemonoxacin247.32

[back to top]

Area Under the Concentration-time Curve (AUC) of Nemonoxacin

"AUC (0-22.5) - Area under the concentration-time curve from 0 to 22.5 hours of Nemonoxacin~AUC(0-∞) - Areas under the concentration-time curve from 0 h to infinity of Nemonoxacin" (NCT03551210)
Timeframe: Day 1 pre-dose and 0, 0.5, 2.5, 4, 6, 12, 16 and 22.5 (= Day 2 pre-dose) hrs after the end of first infusion on Day 1 of treatment

Interventionhours*ng/ml (Mean)
AUC (0-22.5)AUC(0-∞)
Nemonoxacin34372.6938560.90

[back to top]

Nemnoxacin Concentration Changes

"Cmax - The peak Nemonoxacin concentration at Day 1-2 of treatment~C-22.5hours - 22.5-h drug concentration of Nemonoxacin" (NCT03551210)
Timeframe: Day 1 pre-dose and 0, 0.5, 2.5, 4, 6, 12, 16 and 22.5 (= Day 2 pre-dose) hrs after the end of first infusion on Day 1 of treatment

Interventionng/ml (Mean)
CmaxC-22.5hours
Nemonoxacin8163.84359.63

[back to top]

Number of Patients With Microbiological Success

Microbiological response is evaluated as microbiological success if culture study demonstrates eradication of pathogen or no material available for culture because of clinical success (NCT03551210)
Timeframe: Visit 2 (day 4/8 ot treatment), 3 (within 1-2 days after last dose), 4 (within 7-9 days after last dose)

,
InterventionParticipants (Count of Participants)
Visit 2Visit 3Visit 4
Nemonoxacin171919
Tavanic®161616

[back to top]

Number of Patients With Clinical Success as Judged by the Investigator

Clinical response is evaluated as clinical success if: all signs and symptoms of pneumonia are resolved or improved with no worsening or appearance of new signs and symptoms of pneumonia; there is no requirement for additional antibiotic therapy (NCT03551210)
Timeframe: Visit 2(day 4/8 ot treatment), Visit 3 (within 1-2 days after last dose)

InterventionParticipants (Count of Participants)
Visit 272195661Visit 272195662Visit 372195662Visit 372195661
Clinical successClinical non-efficacyIndefinite response
Nemonoxacin164
Tavanic®154
Nemonoxacin4
Tavanic®5
Nemonoxacin1
Nemonoxacin160
Tavanic®151
Nemonoxacin6
Tavanic®7
Nemonoxacin3
Tavanic®8

[back to top]